Alkermes (ALKS) Net Equity Issued and Repurchased (2014)

Alkermes' (ALKS) quarterly Net Equity Issued and Repurchased came in at $248.4 million in Q1 2014.

Alkermes (ALKS) Net Equity Issued and Repurchased (2014) Analysis & Trends

Alkermes (ALKS) has 1 years of Net Equity Issued and Repurchased data on file, last reported at $248.4 million in Q1 2014.

On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to $248.4 million in Q1 2014; TTM through Dec 2014 was $248.4 million, a N/A change from a year earlier, with the FY2014 full-year figure at $248.4 million, changed N/A from the prior year.
Net Equity Issued and Repurchased for Q1 2014 stood at $248.4 million.
Over the last five years, Net Equity Issued and Repurchased for ALKS reached as high as $248.4 million in Q1 2014 and fell as low as $248.4 million in Q1 2014.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Equity Issued and Repurchased (Qtr)
1	Haleon	87.22 Bn	85.35 Bn	-	-
2	Teva Pharmaceutical Industries	39.60 Bn	35.87 Bn	1.97 Bn	-
3	Zoetis	31.46 Bn	29.52 Bn	1.62 Bn	-
4	Takeda Pharmaceutical	26.49 Bn	22.44 Bn	4.39 Bn	-
5	United Therapeutics	23.03 Bn	20.88 Bn	648.10 Mn	-
6	Universe Pharmaceuticals	23.03 Bn	-10.56 Bn	-	-
7	Viatris	20.90 Bn	19.09 Bn	1.16 Bn	500,000.00
8	Neurocrine Biosciences	17.50 Bn	16.19 Bn	800.70 Mn	23.60 Mn
9	Elanco Animal Health	12.33 Bn	11.91 Bn	785.00 Mn	-
10	Alkermes	9.72 Bn	9.21 Bn	331.33 Mn	-

Download Data

Date	Value
Mar 31, 2014	248.41 Mn
Mar 31, 2014	248.41 Mn